摘要
目的:观察阿帕替尼联合卡瑞利珠单抗后线治疗晚期结直肠癌(CRC)的疗效。方法:将64例晚期CRC患者随机分为对照组和观察组,每组32例。对照组患者采用阿帕替尼治疗,观察组患者在对照组治疗方案的基础上联合卡瑞利珠单抗治疗,比较2组患者的疗效、免疫功能、肿瘤标志物、无进展生存时间(PFS)、总生存时间(OS)以及不良反应发生情况。结果:观察组患者疾病控制率高于对照组(P<0.05)。治疗前2组患者免疫功能指标比较差异无统计学意义(P>0.05);治疗后观察组患者CD3^(+)、CD4^(+)水平以及CD4^(+)/CD8^(+)均高于对照组(P<0.05),而CD8^(+)水平低于对照组(P<0.05)。治疗前2组患者肿瘤标志物水平比较差异无统计学意义(P>0.05);治疗后观察组患者癌胚抗原、糖类抗原72-4(CA72-4)以及糖链抗原19-9(CA19-9)水平均低于对照组(P<0.05)。治疗后观察组患者的PFS以及OS均长于对照组(P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论:阿帕替尼与卡瑞利珠单抗联用后线治疗晚期CRC具有较好的疗效,不但能够调节免疫系统,增强免疫功能,而且还可以降低肿瘤标志物水平,延长患者生存期,且不会增加不良反应发生率。
Objective To observe the clinical efficacy of apatinib combined with camrelizumab in the later-line treatment of advanced colorectal cancer(CRC).Methods A total of 64patients with advanced CRC were randomly divided into a control group and an observation group,with 32cases in each group.Patients in the control group were treated with apatinib,while patients in the observation group received apatinib combined with camrelizumab on the basis of the control group's treatment regimen.The efficacy,immune function,tumor markers,progression-free survival time(PFS),overall survival time(OS)and the occurrence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was higher than that of the control group(P<0.05).There was no statistically significant difference in immune function indicators between the two groups before treatment(P>0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05),while the level of CD8^(+)was lower than that in the control group(P<0.05).There was no statistically significant difference in levels of tumor markers between the two groups before treatment(P>0.05).After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen72-4(CA72-4)and carbohydrate antigen19-9(CA19-9)in the observation group were lower than those in the control group(P<0.05).After treatment,the PFS and OS of the observation group were longer than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Apatinib combined with camrelizumab in the later-line treatment of advanced CRC has good efficacy.It can not only regulate the immune system and enhance immune function,but also reduce the levels of tumor markers and prolong the survival time of patients without increasing the incidence of adverse reactions.
作者
李凡
李晓棠
LI Fan;LI Xiao-tang(Department of Oncology,First Affiliated Hospital of Nanyang Medical College,Nanyang,Henan 473000)
出处
《中国肛肠病杂志》
2025年第7期21-24,共4页
Chinese Journal of Coloproctology
作者简介
第一作者:李凡,男,河南驻马店人,住院医师,研究方向:肿瘤相关。E-mail:lifan991@163.com。
